Organon & Co (OGN) Prévision du cours des actions

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. The company has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. The company has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. The company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.